中国耳鼻咽喉头颈外科2026，Vol.33Issue(5)：241-246,6.DOI:10.16066/j.1672-7002.2026.05.001
敲低长链非编码RNA DYNLRB2-AS1通过调控miR-26b-5p抑制喉癌细胞的增殖、迁移和顺铂的耐药性
Knockdown of lncRNA DYNLRB2-AS1 inhibits laryngeal cancer cell proliferation,migration and cisplatin resistance by regulating miR-26b-5p
摘要
Abstract
OBJECTIVE To investigate the expression of long noncoding RNA(lncRNA)DYNLRB2-AS1 in laryngeal cancer tissues and whether it affects the progression of laryngeal cancer by regulating miR-26b-5p activity.METHODS The Lnc2Cancer v2.0 database was used to analyze the expression of DYNLRB2-AS1 in laryngeal cancer tissues and the correlation between DYNLRB2-AS1 expression and overall survival in laryngeal cancer patients.RT-qPCR was used to detect DYNLRB2-AS1 expression in laryngeal cancer cell lines TU138,AMC-HN-8,HLaC78,TU159 and Hep-2.HLaC78 cells were transfected with sh-DYNLRB2-AS1 plasmid and empty vector plasmid,respectively,designated as the si-DYNLRB2-AS1 group and the si-NC group.HLaC78 cell proliferation,migration,and cisplatin resistance were assessed using colony formation assays,wound wound healing assays,and CCK-8 assays.Western blot analysis was used to examine the expression of drug resistance-associated proteins ERCC1,COX-2,P-gp,and XRCC1 in HLaC78 cells.Dual-luciferase reporter assays were used to validate the targeted binding of DYNLRB2-AS1 to miR-26b-5p.The correlation between DYNLRB2-AS1 and miR-26b-5p expression in laryngeal cancer tissues was analyzed using the Lnc2Cancer v2.0 database.RT-qPCR was used to examine the effect of DYNLRB2-AS1 knockdown on miR-26b-5p expression in HLaC78 cells.RESULTS DYNLRB2-AS1 expression was significantly higher in laryngeal cancer tissues than in normal laryngeal tissues(t=23.35,P<0.01).Patients with low DYNLRB2-AS1 expression had longer overall survival than those with high DYNLRB2-AS1 expression(χ2=11.05,P<0.01).Compared with immortalized laryngeal epithelial HLEC cells,DYNLRB2-AS1 was highly expressed in various laryngeal cancer cell lines(all P<0.01).Compared with the si-NC group,inhibition of DYNLRB2-AS1 significantly reduced the number of HLaC78 cell colonies(226.40±12.74 vs.80.62±7.09,t=9.99,P<0.01),the migration rate of HLaC78 cells(54.48%±5.35%vs.21.53%±3.39%,t=5.21,P<0.01),and the half-maximal inhibitory concentration(IC50)of the drug in HLaC78 cells(6.88±0.80 vs.12.40±1.55,t=6.33,P<0.01).Compared with the si-NC group,the expression of ERCC1,COX-2,P-gp,and XRCC1 in HLaC78 cells in the si-DYNLRB2-AS1 group was significantly decreased(P<0.01).DYNLRB2-AS1 could target and bind to miR-26b-5p(P<0.01).The expression of DYNLRB2-AS1 and miR-26b-5p was negatively correlated in laryngeal cancer tissues(P<0.01).Compared with the si-NC group,knockdown of DYNLRB2-AS1 significantly increased the expression of miR-26b-5p in HLaC78 cells(6.90±0.94 vs.1.05±0.24,t=6.02,P<0.01).CONCLUSION The expression of DYNLRB2-AS1 was significantly increased in laryngeal cancer tissues.Knockdown of DYNLRB2-AS1 inhibited the proliferation,migration and cisplatin resistance of laryngeal cancer HLaC78 cells by promoting the expression of miR-26b-5p.关键词
喉肿瘤/细胞增殖/细胞迁移分析/耐药性/DYNLRB2-AS1/miR-26b-5pKey words
Laryngeal Neoplasms/Cell Proliferation/Cell Migration Assays/Tolerance/DYNLRB2-AS1/miR-26b-5p引用本文复制引用
常昆鹏,陈一博,李斐,杨涛..敲低长链非编码RNA DYNLRB2-AS1通过调控miR-26b-5p抑制喉癌细胞的增殖、迁移和顺铂的耐药性[J].中国耳鼻咽喉头颈外科,2026,33(5):241-246,6.基金项目
国家自然科学基金(82002895) （82002895）
